Diffuse large cell lymphoma. Prognostic factors with treatment

David J. Straus, George Wong, Joachim Yahalom, George Varsos, Subhash Gulati, Bayard Clarkson

Research output: Contribution to journalArticlepeer-review

10 Scopus citations

Abstract

Five successive chemotherapy protocols for stages II, III and IV diffuse large cell lymphoma (DLCL) have resulted in identical overall survivals. Between 35% to 45% of patients survived. In a multivariate analysis employing the Weibull model 3 factors were associated with shortened survival: bulky mediastinal and/or retroperitoneal disease, elevated serum LDH and advanced age. In young patients with bulky mediastinal and/or retroperitoneal disease and high serum LDH, autologous bone marrow transplantation following high dose chemotherapy and radiation therapy (RT) as part of the initial-treatment have produced more promising results. In a randomized trial, a significantly longer disease-free survival was found for patients with stages I or IE diffuse lymphomas with RT followed by adjuvant chemotherapy than with RT alone.

Original languageEnglish
Pages (from-to)32-36
Number of pages5
JournalLeukemia
Volume5
Issue numberSUPPL. 1
StatePublished - 1991
Externally publishedYes

Fingerprint

Dive into the research topics of 'Diffuse large cell lymphoma. Prognostic factors with treatment'. Together they form a unique fingerprint.

Cite this